Nanobac Pharmaceuticals, Incorporated
NNBP
$0.00
$0.000.00%
OTC PK
| 12/31/2007 | 09/30/2007 | 06/30/2007 | 03/31/2007 | 12/31/2006 | |
|---|---|---|---|---|---|
| Revenue | 4.40K | 5.80K | 2.40K | 5.00K | 2.30K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.40K | 5.80K | 2.40K | 5.00K | 2.30K |
| Cost of Revenue | 3.70K | 4.70K | 1.90K | 4.30K | 700.00 |
| Gross Profit | 700.00 | 1.10K | 500.00 | 800.00 | 1.60K |
| SG&A Expenses | 321.90K | 163.20K | 279.50K | 2.06M | 409.80K |
| Depreciation & Amortization | 113.80K | 114.60K | 115.30K | 116.60K | 117.40K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 665.80K | 541.30K | 681.80K | 2.56M | 1.38M |
| Operating Income | -661.40K | -535.50K | -679.40K | -2.56M | -1.38M |
| Income Before Tax | -1.17M | -835.80K | -716.60K | -3.86M | -1.30M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.17M | -835.80K | -716.60K | -3.86M | -1.30M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.17M | -835.80K | -716.60K | -3.86M | -1.30M |
| EBIT | -661.40K | -535.50K | -679.40K | -2.56M | -1.38M |
| EBITDA | -547.60K | -420.90K | -564.10K | -2.44M | -1.26M |
| EPS Basic | 0.00 | 0.00 | 0.00 | -0.02 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | -0.02 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| Average Basic Shares Outstanding | 250.38M | 247.47M | 247.47M | 233.17M | 205.54M |
| Average Diluted Shares Outstanding | 250.38M | 247.47M | 247.47M | 233.17M | 205.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |